0000891293-15-000062.txt : 20151204 0000891293-15-000062.hdr.sgml : 20151204 20151204183030 ACCESSION NUMBER: 0000891293-15-000062 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20151204 FILED AS OF DATE: 20151204 DATE AS OF CHANGE: 20151204 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CTI BIOPHARMA CORP CENTRAL INDEX KEY: 0000891293 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 911533912 STATE OF INCORPORATION: WA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3101 WESTERN AVENUE STREET 2: SUITE 600 CITY: SEATTLE STATE: WA ZIP: 98121 BUSINESS PHONE: 2062827100 MAIL ADDRESS: STREET 1: 3101 WESTERN AVENUE STREET 2: SUITE 600 CITY: SEATTLE STATE: WA ZIP: 98121 FORMER COMPANY: FORMER CONFORMED NAME: CELL THERAPEUTICS INC DATE OF NAME CHANGE: 19960321 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Plunkett Matthew CENTRAL INDEX KEY: 0001557551 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-12465 FILM NUMBER: 151271014 MAIL ADDRESS: STREET 1: 3101 WESTERN AVENUE, SUITE 600 CITY: SEATTLE STATE: WA ZIP: 98121 4 1 primary_doc.xml PRIMARY DOCUMENT X0306 4 2015-12-04 0 0000891293 CTI BIOPHARMA CORP ctic 0001557551 Plunkett Matthew 3101 WESTERN AVENUE, SUITE 600 SEATTLE WA 98121 0 1 0 0 EVP, Corporate Development Common Stock 2015-12-04 4 S 0 1500 0.9901 D 628584 D Common Stock 2015-12-04 4 S 0 600 0.9902 D 627984 D Common Stock 2015-12-04 4 S 0 200 0.9924 D 627784 D Common Stock 2015-12-04 4 S 0 200 0.9935 D 627584 D Common Stock 2015-12-04 4 S 0 1100 0.9947 D 626484 D Common Stock 2015-12-04 4 S 0 200 0.9948 D 626284 D Common Stock 2015-12-04 4 S 0 600 0.995 D 625684 D Common Stock 2015-12-04 4 S 0 100 0.9975 D 625584 D Common Stock 2015-12-04 4 S 0 100 0.9995 D 625484 D Common Stock 2015-12-04 4 S 0 300 0.9996 D 625184 D Common Stock 2015-12-04 4 S 0 200 0.9998 D 624984 D Common Stock 2015-12-04 4 S 0 100 0.9999 D 624884 D Common Stock 2015-12-04 4 S 0 4500 1 D 620384 D Common Stock 2015-12-04 4 S 0 100 1.005 D 620284 D Common Stock 2015-12-04 4 S 0 200 1.01 D 620084 D The sale was effected pursuant to a 10b5-1 trading plan. By: Louis A. Bianco, Attorney-in-Fact For: Matthew Plunkett 2015-12-04